Machine learning to predict developmental neurotoxicity with high-throughput data from 2D bio-engineered tissues.

There is a growing need for fast and accurate methods for testing developmental neurotoxicity across several chemical exposure sources. Current approaches, such as in vivo animal studies, and assays of animal and human primary cell cultures, suffer from challenges related to time, cost, and applicability to human physiology. Prior work has demonstrated success employing machine learning to predict developmental neurotoxicity using gene expression data collected from human 3D tissue models exposed to various compounds. The 3D model is biologically similar to developing neural structures, but its complexity necessitates extensive expertise and effort to employ. By instead focusing solely on constructing an assay of developmental neurotoxicity, we propose that a simpler 2D tissue model may prove sufficient. We thus compare the accuracy of predictive models trained on data from a 2D tissue model with those trained on data from a 3D tissue model, and find the 2D model to be substantially more accurate. Furthermore, we find the 2D model to be more robust under stringent gene set selection, whereas the 3D model suffers substantial accuracy degradation. While both approaches have advantages and disadvantages, we propose that our described 2D approach could be a valuable tool for decision makers when prioritizing neurotoxicity screening.

Markov Logic Networks for Adverse Drug Event Extraction from Text.

Adverse drug events (ADEs) are a major concern and point of emphasis for the medical profession, government, and society. A diverse set of techniques from epidemiology, statistics, and computer science are being proposed and studied for ADE discovery from observational health data (e.g., EHR and claims data), social network data (e.g., Google and Twitter posts), and other information sources. Methodologies are needed for evaluating, quantitatively measuring, and comparing the ability of these various approaches to accurately discover ADEs. This work is motivated by the observation that text sources such as the Medline/Medinfo library provide a wealth of information on human health. Unfortunately, ADEs often result from unexpected interactions, and the connection between conditions and drugs is not explicit in these sources. Thus, in this work we address the question of whether we can quantitatively estimate relationships between drugs and conditions from the medical literature. This paper proposes and studies a state-of-the-art NLP-based extraction of ADEs from text.

Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data.

Several prominent public health hazards [29] that occurred at the beginning of this century due to adverse drug events (ADEs) have raised international awareness of governments and industries about pharmacovigilance (PhV) [6,7], the science and activities to monitor and prevent adverse events caused by pharmaceutical products after they are introduced to the market. A major data source for PhV is large-scale longitudinal observational databases (LODs) [6] such as electronic health records (EHRs) and medical insurance claim databases. Inspired by the Self-Controlled Case Series (SCCS) model [27], arguably the leading method for ADE discovery from LODs, we propose baseline regularization, a regularized generalized linear model that leverages the diverse health profiles available in LODs across different individuals at different times. We apply the proposed method as well as SCCS to the Marshfield Clinic EHR. Experimental results suggest that the proposed method outperforms SCCS under various settings in identifying benchmark ADEs from the Observational Medical Outcomes Partnership ground truth [26].

Score As You Lift (SAYL): A Statistical Relational Learning Approach to Uplift Modeling.

We introduce Score As You Lift (SAYL), a novel Statistical Relational Learning (SRL) algorithm, and apply it to an important task in the diagnosis of breast cancer. SAYL combines SRL with the marketing concept of uplift modeling, uses the area under the uplift curve to direct clause construction and final theory evaluation, integrates rule learning and probability assignment, and conditions the addition of each new theory rule to existing ones. Breast cancer, the most common type of cancer among women, is categorized into two subtypes: an earlier in situ stage where cancer cells are still confined, and a subsequent invasive stage. Currently older women with in situ cancer are treated to prevent cancer progression, regardless of the fact that treatment may generate undesirable side-effects, and the woman may die of other causes. Younger women tend to have more aggressive cancers, while older women tend to have more indolent tumors. Therefore older women whose in situ tumors show significant dissimilarity with in situ cancer in younger women are less likely to progress, and can thus be considered for watchful waiting. Motivated by this important problem, this work makes two main contributions. First, we present the first multi-relational uplift modeling system, and introduce, implement and evaluate a novel method to guide search in an SRL framework. Second, we compare our algorithm to previous approaches, and demonstrate that the system can indeed obtain differential rules of interest to an expert on real data, while significantly improving the data uplift.

Predicting the secondary structure of proteins using machine learning algorithms.

The functions of proteins in living organisms are related to their 3-D structure, which is known to be ultimately determined by their linear sequence of amino acids that together form these macromolecules. It is, therefore, of great importance to be able to understand and predict how the protein 3D-structure arises from a particular linear sequence of amino acids. In this paper we report the application of Machine Learning methods to predict, with high values of accuracy, the secondary structure of proteins, namely alpha-helices and beta-sheets, which are intermediate levels of the local structure.

Identifying Adverse Drug Events by Relational Learning.

The pharmaceutical industry, consumer protection groups, users of medications and government oversight agencies are all strongly interested in identifying adverse reactions to drugs. While a clinical trial of a drug may use only a thousand patients, once a drug is released on the market it may be taken by millions of patients. As a result, in many cases adverse drug events (ADEs) are observed in the broader population that were not identified during clinical trials. Therefore, there is a need for continued, post-marketing surveillance of drugs to identify previously-unanticipated ADEs. This paper casts this problem as a reverse machine learning task, related to relational subgroup discovery and provides an initial evaluation of this approach based on experiments with an actual EMR/EHR and known adverse drug events.

Demand-Driven Clustering in Relational Domains for Predicting Adverse Drug Events.

Learning from electronic medical records (EMR) is challenging due to their relational nature and the uncertain dependence between a patient's past and future health status. Statistical relational learning is a natural fit for analyzing EMRs but is less adept at handling their inherent latent structure, such as connections between related medications or diseases. One way to capture the latent structure is via a relational clustering of objects. We propose a novel approach that, instead of pre-clustering the objects, performs a demand-driven clustering during learning. We evaluate our algorithm on three real-world tasks where the goal is to use EMRs to predict whether a patient will have an adverse reaction to a medication. We find that our approach is more accurate than performing no clustering, pre-clustering, and using expert-constructed medical heterarchies.

A relational learning approach to Structure-Activity Relationships in drug design toxicity studies.

It has been recognized that the development of new therapeutic drugs is a complex and expensive process. A large number of factors affect the activity in vivo of putative candidate molecules and the propensity for causing adverse and toxic effects is recognized as one of the major hurdles behind the current "target-rich, lead-poor" scenario. Structure-Activity Relationship (SAR) studies, using relational Machine Learning (ML) algorithms, have already been shown to be very useful in the complex process of rational drug design. Despite the ML successes, human expertise is still of the utmost importance in the drug development process. An iterative process and tight integration between the models developed by ML algorithms and the know-how of medicinal chemistry experts would be a very useful symbiotic approach. In this paper we describe a software tool that achieves that goal--iLogCHEM. The tool allows the use of Relational Learners in the task of identifying molecules or molecular fragments with potential to produce toxic effects, and thus help in stream-lining drug design in silico. It also allows the expert to guide the search for useful molecules without the need to know the details of the algorithms used. The models produced by the algorithms may be visualized using a graphical interface, that is of common use amongst researchers in structural biology and medicinal chemistry. The graphical interface enables the expert to provide feedback to the learning system. The developed tool has also facilities to handle the similarity bias typical of large chemical databases. For that purpose the user can filter out similar compounds when assembling a data set. Additionally, we propose ways of providing background knowledge for Relational Learners using the results of Graph Mining algorithms.